- Home
- SCLX vs AKYA Comparison
SCLX vs AKYA Comparison
Compare SCLX & AKYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- AKYA
- Stock Information
- Founded
- SCLX 2011
- AKYA 2015
- Country
- SCLX United States
- AKYA United States
- Employees
- SCLX N/A
- AKYA N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- AKYA Medical Specialities
- Sector
- SCLX Health Care
- AKYA Industrials
- Exchange
- SCLX Nasdaq
- AKYA Nasdaq
- Market Cap
- SCLX 130.1M
- AKYA 145.5M
- IPO Year
- SCLX N/A
- AKYA 2021
- Fundamental
- Price
- SCLX $0.61
- AKYA $2.41
- Analyst Decision
- SCLX Strong Buy
- AKYA Buy
- Analyst Count
- SCLX 3
- AKYA 8
- Target Price
- SCLX $11.33
- AKYA $4.60
- AVG Volume (30 Days)
- SCLX 184.3K
- AKYA 159.6K
- Earning Date
- SCLX 11-26-2024
- AKYA 11-14-2024
- Dividend Yield
- SCLX N/A
- AKYA N/A
- EPS Growth
- SCLX N/A
- AKYA N/A
- EPS
- SCLX N/A
- AKYA N/A
- Revenue
- SCLX $50,833,000.00
- AKYA $86,815,000.00
- Revenue This Year
- SCLX $32.77
- AKYA $3.66
- Revenue Next Year
- SCLX $50.71
- AKYA $18.18
- P/E Ratio
- SCLX N/A
- AKYA N/A
- Revenue Growth
- SCLX 9.41
- AKYA N/A
- 52 Week Low
- SCLX $0.54
- AKYA $1.88
- 52 Week High
- SCLX $2.63
- AKYA $6.31
- Technical
- Relative Strength Index (RSI)
- SCLX 28.71
- AKYA 35.21
- Support Level
- SCLX $0.73
- AKYA $3.10
- Resistance Level
- SCLX $1.14
- AKYA $3.26
- Average True Range (ATR)
- SCLX 0.11
- AKYA 0.20
- MACD
- SCLX -0.04
- AKYA -0.03
- Stochastic Oscillator
- SCLX 11.99
- AKYA 26.63
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About AKYA Akoya BioSciences Inc.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.